11/4/2024

Levothyroxine Sodium Injection

Products Affected - Description

- Levothyroxine sodium solution for injection, Fresenius Kabi, 100 mcg/mL (500 mcg), 5 mL single dose vial, NDC 63323-0895-10
- Levothyroxine sodium solution for injection, Fresenius Kabi, 20 mcg/mL (100 mcg), 5 mL single dose vial, NDC 63323-0885-10
- Levothyroxine sodium solution for injection, Fresenius Kabi, 40 mcg/mL (200 mcg), 5 mL single dose vial, NDC 63323-0890-10

Reason for the Shortage

- Fresenius Kabi has levothyroxine injection available.
- Par has levothyroxine injection available.
- Piramal Critical Care discontinued levothyroxine injection in late-2022.
- Sagent has levothyroxine injection available.

Available Products

- Levothyroxine sodium powder for solution for injection, Fresenius Kabi, 500 mcg single dose vial, NDC 63323-0648-10
- Levothyroxine sodium powder for solution for injection, Fresenius Kabi, 200 mcg single dose vial, NDC 63323-0647-10
- Levothyroxine sodium powder for solution for injection, Fresenius Kabi, 100 mcg single dose vial, NDC 63323-0649-07
- Levothyroxine sodium powder for solution for injection, Par Pharmaceuticals, 500 mcg single dose vial, NDC 42023-0203-01
- Levothyroxine sodium powder for solution for injection, Par Pharmaceuticals, 200 mcg single dose vial, NDC 42023-0202-01
- Levothyroxine sodium powder for solution for injection, Par Pharmaceuticals, 100 mcg single dose vial, NDC 42023-0201-01
- Levothyroxine sodium powder for solution for injection, Sagent, 100 mcg single dose vial, 1 count, NDC 25021-0468-10
- Levothyroxine sodium powder for solution for injection, Sagent, 500 mcg single dose vial, 1 count, NDC 25021-0470-10
- Levothyroxine sodium powder for solution for injection, Sagent, 200 mcg single dose vial, 1 count, NDC 25021-0469-10

Estimated Resupply Dates

- Fresenius Kabi has short-dated levothyroxine 40 mcg/mL 5 mL vials and 100 mcg/mL 5 mL vials available with an expiration date of < 7 months. The 20 mcg/mL 5 mL vials are on back order and the company estimates a release date of early-November 2024.

Updated

Updated November 4, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created February 16, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.